Brief: Ryvu Therapeutics Sa Says Plan To Initiate Remark Study In First Half Of 2024

Ryvu Therapeutics SA

20/10/2023 07:13

Oct 20 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * EXPANSION OF CLINICAL DEVELOPMENT OF RVU120 IN LOW-RISK
MYELODYSPLASTIC SYNDROMES (LR-MDS)
    * RYVU THERAPEUTICS SA - ENTERED INTO CLINICAL TRIAL
FINANCIAL
SUPPORT AGREEMENT FOR INVESTIGATOR INITIATED CLINICAL TRIAL WITH
EUROPEAN EMSCO NETWORK
    * RYVU THERAPEUTICS SA -  REMARK STUDY IS AN ESSENTIAL
ELEMENT OF
IMPLEMENTING RYVU'S DEVELOPMENT PLANS FOR 2022-2024
    * RYVU THERAPEUTICS SA - PLAN TO INITIATE REMARK STUDY IN
FIRST
HALF OF 2024

Source text for Eikon:  ID:nPnbqTf3ga 
Further company coverage:  RVU.WA 

 ((Reuters.Briefs@thomsonreuters.com;;))